![semaglutide 2.4 mg weekly PDF] 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://figures.semanticscholar.org/898978c1b0543b943d605e293f5296fb7568cee7/9-Table2-1.png)
![semaglutide 2.4 mg weekly PDF] 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://scx2.b-cdn.net/gfx/news/hires/2025/ozempic-4.jpg)
![semaglutide 2.4 mg weekly PDF] 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://www.mountainside-medical.com/cdn/shop/files/Wegovy-_semaglutide_-Weight-Loss-Pen-Injector-2.4-mg.jpg?v=1684507038)
![semaglutide 2.4 mg weekly PDF] 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://www.clinicalnutritioncenter.com/wp-content/uploads/2021/02/semaglutide-weight-loss.jpg)
semaglutide 2.4 mg weekly
Shipping Estimate
semaglutide 2.4 mg weekly PDF] 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine
USD24.73
USD54.73
Pay in 4 interest-free payments of $6.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://www.tallpiscesgirl.com/wp-content/uploads/2026/01/Wegovy-semaglutide-2.4-mg-a-once-weekly-injectable-medication-by-Novo-Nordisk-is-now-available-in-Malaysia.jpg)
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=2806170360983997912)
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://cdn11.bigcommerce.com/s-6vlqtpwpny/images/stencil/1280x1280/products/2389/2717/Wegovy_2.4mg__40789.1684876366.jpg?c=2)
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3835176134871127091)
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/brand/obesity/wegovy/dosing-administration/wegovy-dosing/switch-from-pen-pill.png)
![semaglutide 2.4 mg weekly PDF] 24 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Novo Nordisk Launches Obesity Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-026-04416-4/MediaObjects/41591_2026_4416_Fig2_HTML.png)
